Monday, June 14, 2021 10:25:59 AM
Great Questions Three paragraphs
1st Paragraph; %% drop from a reverse. Combine this with the unknowns with a new CEO its a disaster. The drop can easily be 50%. This is why the Fake Research Report types are always promoting a reverse split. If I had the courage to short a company like CYDY I would be all over asking and demanding a payday; a reverse split.
Do I suspect a Reverse Split due to the probably 750,000,000 shares and Warrants combined. Yes. The new CEO can blame Nader.
I was the new CEO I would do a 1 for 10 reverse. Shares might bounce to 10$ We would then have around 75,000,000 shares.
Remove the problem. It was Nader's problem and not mine. I would then raise 200 to 300,000,000$. Only a top dog Bio management type could pull that off. Lets say it was 300,000,000$ raised. That's 30,000,000 new shares. Now we have 105,000,000 shares with an authorized 800,000,000 shares.
I would remove short seller talking points one by one.
New CEO with a track record? This is a problem that a track record cant solve. CYDY will destroy the cash flows of many Big Pharma and hence about 40% of the cash flow the FDA pays its worthless employees with. Yes, Worthless. Post this to the office door.
Para 2; I reject the question as not proven in an honest FDA Trial. That was easy. Evidence is available that proves this. The FDA is corrupt. Possibly a new Covid supper killer might bring this institution to its knees. I ask; how many dead will the USA populace allow the FDA to have their corruption cause.
Para 3;Could Nader add shares to fight the 13-D dudes. Sure. He might. But for many reasons I doubt he will. If he loses, he retires a multi millionaire.
Most importantly, a new CEO must never over promise and under deliver. Great CEOs know this simple fact.
1st Paragraph; %% drop from a reverse. Combine this with the unknowns with a new CEO its a disaster. The drop can easily be 50%. This is why the Fake Research Report types are always promoting a reverse split. If I had the courage to short a company like CYDY I would be all over asking and demanding a payday; a reverse split.
Do I suspect a Reverse Split due to the probably 750,000,000 shares and Warrants combined. Yes. The new CEO can blame Nader.
I was the new CEO I would do a 1 for 10 reverse. Shares might bounce to 10$ We would then have around 75,000,000 shares.
Remove the problem. It was Nader's problem and not mine. I would then raise 200 to 300,000,000$. Only a top dog Bio management type could pull that off. Lets say it was 300,000,000$ raised. That's 30,000,000 new shares. Now we have 105,000,000 shares with an authorized 800,000,000 shares.
I would remove short seller talking points one by one.
New CEO with a track record? This is a problem that a track record cant solve. CYDY will destroy the cash flows of many Big Pharma and hence about 40% of the cash flow the FDA pays its worthless employees with. Yes, Worthless. Post this to the office door.
Para 2; I reject the question as not proven in an honest FDA Trial. That was easy. Evidence is available that proves this. The FDA is corrupt. Possibly a new Covid supper killer might bring this institution to its knees. I ask; how many dead will the USA populace allow the FDA to have their corruption cause.
Para 3;Could Nader add shares to fight the 13-D dudes. Sure. He might. But for many reasons I doubt he will. If he loses, he retires a multi millionaire.
Most importantly, a new CEO must never over promise and under deliver. Great CEOs know this simple fact.
Recent CYDY News
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
